Standard BioTools Inc. (FLB.F)

2.2800 +0.0200 (+0.88%) At close: 08:01AM CEST

Standard BioTools Inc.

2 Tower Place
Suite 2000
South San Francisco, CA 94080
United States
650 266 6000
https://www.standardbio.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 534

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Egholm Ph.D.	President, CEO & Director	1.28M	N/A	1963
Dr. Shane Bowen Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Adam Taich	Chief Strategy Officer	N/A	N/A	1976

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Corporate governance

Standard BioTools Inc.’s ISS governance QualityScore as of 29 April 2024 is 10. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.